US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CG Oncology Inc.

24.17

-0.0100-0.04%

Post-market: 24.170.00000.00%17:19 EDT

Volume:2.01M

Turnover:48.35M

Market Cap:1.84B

PE:-17.16

High:24.38

Open:24.09

Low:23.32

Close:24.18

Loading ...

Overview Company News Filings

CG Oncology Price Target Maintained With a $66.00/Share by RBC Capital

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Analysts Offer Insights on NA Companies: Rubrik, Inc. Class A (RBRK) and CG Oncology, Inc. (CGON)

CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co.

Promising Clinical Results and Strategic Positioning: CG Oncology Recommended as a Buy

Buy Rating Recommended for CG Oncology Due to Promising Phase 3 Trial Results of Cretostimogene

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

CG Oncology, Inc.: A Strong Buy on Promising NMIBC Treatment Cretostimogene

Analysts’ Top NA Picks: GE Vernova Inc. (GEV), CG Oncology, Inc. (CGON)

CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate

CG Oncology Reports Promising Phase 3 Trial Results

CG Oncology announces data from Phase 3 BOND-003 trial

BRIEF-CG Oncology Announces 74.5% Complete Response In Phase 3 Trial

CG Oncology Inc - Announces 74.5% Complete Response in Phase 3 Trial

THOMSON REUTERS

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer

THOMSON REUTERS

CG Oncology Inc - No Grade 3 or Greater Treatment-Related Adverse Events Reported

THOMSON REUTERS

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CGON/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CGON","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGON\",,,,,undefined,":{"symbol":"CGON","market":"US","secType":"STK","nameCN":"CG Oncology Inc.","latestPrice":24.17,"timestamp":1747252800000,"preClose":24.18,"halted":0,"volume":2010127,"hourTrading":{"tag":"盘后","latestPrice":24.17,"preClose":24.17,"latestTime":"17:19 EDT","volume":492144,"amount":11895120.48,"timestamp":1747257584845},"delay":0,"floatShares":61123015,"shares":76221857,"eps":-1.408697,"marketStatus":"Post-Mkt","change":-0.01,"latestTime":"05-14 17:37:33 EDT","open":24.09,"high":24.38,"low":23.32,"amount":48353245.172267,"amplitude":0.043838,"askPrice":28.97,"askSize":100,"bidPrice":24.2,"bidSize":39,"shortable":3,"etf":0,"ttmEps":-1.408697,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1747267200000},"marketStatusCode":4,"adr":0,"listingDate":1706158800000,"exchange":"NASDAQ","adjPreClose":24.18,"preHourTrading":{"tag":"盘前","latestPrice":24.01,"preClose":24.18,"latestTime":"09:25 EDT","volume":1001,"amount":24033.210201,"timestamp":1747229146909},"postHourTrading":{"tag":"盘后","latestPrice":24.17,"preClose":24.17,"latestTime":"17:19 EDT","volume":492144,"amount":11895120.48,"timestamp":1747257584845},"volumeRatio":0.955009,"impliedVol":0.5778,"impliedVolPercentile":0.276},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGON\",,,,,undefined,":{"symbol":"CGON","floatShares":61123015,"roa":"-15.02%","roe":"-19.18%","lyrEps":-1.408697,"volumeRatio":0.955009,"shares":76221857,"dividePrice":0,"high":24.38,"amplitude":0.043838,"preClose":24.18,"low":23.32,"week52Low":14.8,"pbRate":"2.51","psRate":"1617.46","week52High":40.47,"institutionHeld":0,"latestPrice":24.17,"committee":-0.438849,"eps":-1.408697,"divideRate":0,"volume":2010127,"delay":0,"ttmEps":-1.408697,"open":24.09,"prevYearClose":28.68,"prevWeekClose":23.74,"prevMonthClose":26.94,"prevQuarterClose":24.49,"fiveDayClose":22.34,"twentyDayClose":20.11,"sixtyDayClose":27.37},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CGON\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2489239717","title":"CG Oncology Price Target Maintained With a $66.00/Share by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2489239717","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489239717?lang=en_us&edition=fundamental","pubTime":"2024-12-06 22:58","pubTimestamp":1733497080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 06, 2024 09:58 ET (14:58 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CG","CGON"],"gpt_icon":0},{"id":"2489373287","title":"SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2489373287","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489373287?lang=en_us&edition=fundamental","pubTime":"2024-12-06 21:00","pubTimestamp":1733490000,"startTime":"0","endTime":"0","summary":"Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC. “There remains a significant unmet need for treating NMIBC, and this fellowship will help advance research and drive innovation, leading to improvements in patient care,” said Sia Daneshmand, MD, Director of Urologic Oncology at USC/Norris Comprehensive Cancer Center and Chair of the Bladder Cancer Committee of the SUO-CTC.Colin Dinney, MD, Chairman, Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, continued, “We are fortunate to have a very bright and motivated next generation of urologists coming into the field, and this is a great opportunity for them to collaborate with their mentors and present it at a prominent forum like AUA in 2026.”About Bladder CancerMore than 83,000 people are estimated to be diagnosed with bladder cancer in 2024. NMIBC is the most common form of bladder cancer, rep","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PGAn7Ub.kbtQmM44hCDcNw--~B/aD0xOTE7dz0xMTI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/15e379d5feda7db9477b0d6dfc1496ab","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PGAn7Ub.kbtQmM44hCDcNw--~B/aD0xOTE7dz0xMTI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/15e379d5feda7db9477b0d6dfc1496ab"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/suo-ctc-cg-oncology-announce-130000570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","BK4139","IE00BGHQF748.EUR","CGON","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","CG"],"gpt_icon":0},{"id":"2489816162","title":"Analysts Offer Insights on NA Companies: Rubrik, Inc. Class A (RBRK) and CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489816162","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489816162?lang=en_us&edition=fundamental","pubTime":"2024-12-06 20:13","pubTimestamp":1733487216,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Rubrik, Inc. Class A (RBRK – Research Report) and CG Oncolog...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-rubrik-inc-class-a-rbrk-and-cg-oncology-inc-cgon?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-rubrik-inc-class-a-rbrk-and-cg-oncology-inc-cgon?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4139","CGON","IE00BGHQF748.EUR","RBRK","NA","BK4097","CG","BK4141"],"gpt_icon":0},{"id":"2489074124","title":"CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2489074124","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489074124?lang=en_us&edition=fundamental","pubTime":"2024-12-06 18:41","pubTimestamp":1733481660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 06, 2024 05:41 ET (10:41 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","CG"],"gpt_icon":0},{"id":"2489404378","title":"Promising Clinical Results and Strategic Positioning: CG Oncology Recommended as a Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2489404378","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489404378?lang=en_us&edition=fundamental","pubTime":"2024-12-06 17:55","pubTimestamp":1733478945,"startTime":"0","endTime":"0","summary":"Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associate...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-clinical-results-and-strategic-positioning-cg-oncology-recommended-as-a-buy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-clinical-results-and-strategic-positioning-cg-oncology-recommended-as-a-buy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BGHQF748.EUR","LU1201861249.SGD","LU0130518102.USD","IE00BKVL7J92.USD","BK4581","LU2133065610.SGD","IE00BFXG1179.USD","LU0234572021.USD","IE00B19Z3B42.SGD","LU0306807586.USD","LU0310800965.SGD","LU1894683264.USD","LU0320765646.SGD","LU1366192091.USD","LU2129689431.USD","LU1201861165.SGD","BK4553","LU1496350171.SGD","BK4585","LU1162221912.USD","LU0052756011.USD","CG","LU0106831901.USD","BK4559","IE00BBT3K403.USD","LU1496350502.SGD","IE00B64PRP62.GBP","LU0170899867.USD","CGON","LU2129689605.HKD","IE0002270589.USD","LU0208291251.USD","LU0256863902.USD","IE00BLSP4452.SGD","LU0053666078.USD","LU0648000940.SGD","LU0070302665.USD","BK4534","LU0256863811.USD","BAC","IE00BZ1G4Q59.USD","LU0130102774.USD","IE00B19Z3581.USD","LU0098860793.USD","LU0128525689.USD","LU1280957306.USD","IE00B3QW5Z07.USD","BK4135","LU0321505868.SGD","LU1074936037.SGD"],"gpt_icon":0},{"id":"2489106445","title":"Buy Rating Recommended for CG Oncology Due to Promising Phase 3 Trial Results of Cretostimogene","url":"https://stock-news.laohu8.com/highlight/detail?id=2489106445","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489106445?lang=en_us&edition=fundamental","pubTime":"2024-12-06 07:46","pubTimestamp":1733442361,"startTime":"0","endTime":"0","summary":"Analyst Jeffrey Hung of Morgan Stanley maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), retaining the price target of $55.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-recommended-for-cg-oncology-due-to-promising-phase-3-trial-results-of-cretostimogene?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-recommended-for-cg-oncology-due-to-promising-phase-3-trial-results-of-cretostimogene?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CG","CGON"],"gpt_icon":0},{"id":"2489497365","title":"Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2489497365","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489497365?lang=en_us&edition=fundamental","pubTime":"2024-12-06 04:10","pubTimestamp":1733429412,"startTime":"0","endTime":"0","summary":"Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us?Forward this newsletter to them. They can also subscribe here.By Nancy LapidDec 5  - Hello Health Rounds Readers!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nL2N3N60XP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2489961054","title":"CG Oncology, Inc.: A Strong Buy on Promising NMIBC Treatment Cretostimogene","url":"https://stock-news.laohu8.com/highlight/detail?id=2489961054","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489961054?lang=en_us&edition=fundamental","pubTime":"2024-12-06 02:34","pubTimestamp":1733423640,"startTime":"0","endTime":"0","summary":"Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price target...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cg-oncology-inc-a-strong-buy-on-promising-nmibc-treatment-cretostimogene?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cg-oncology-inc-a-strong-buy-on-promising-nmibc-treatment-cretostimogene?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B3QW5Z07.USD","BK4135","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","CGON","CG"],"gpt_icon":0},{"id":"2489981164","title":"Analysts’ Top NA Picks: GE Vernova Inc. (GEV), CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489981164","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489981164?lang=en_us&edition=fundamental","pubTime":"2024-12-06 01:32","pubTimestamp":1733419933,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on GE Vernova Inc. (GEV – Research Report) and CG Oncology, Inc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-na-picks-ge-vernova-inc-gev-cg-oncology-inc-cgon?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-na-picks-ge-vernova-inc-gev-cg-oncology-inc-cgon?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2264538146.SGD","BK4585","BK4187","BK4501","LU0354030511.USD","LU0724618433.USD","BK4141","BK4182","LU1093756168.USD","CG","LU0149725797.USD","LU1988902786.USD","IE00B64PRP62.GBP","BK4206","BK4588","LU0820561818.USD","LU0124384867.USD","LU0820562030.AUD","LU0157215616.USD","LU1064131342.USD","LU1551013425.SGD","LU2098885051.SGD","LU0820561909.HKD","LU0868494617.USD","CGON","LU2756315664.SGD","LU0943347566.SGD","GE","LU1093756325.SGD","BK4135","LU1366333091.USD","GEV","LU2756315318.SGD","BK4566","LU0354030438.USD","IE00B3QW5Z07.USD","LU1303367103.USD","NA","LU1280957306.USD","LU1261432733.SGD","LU2298322129.HKD","IE00BGHQF748.EUR","LU1978683503.SGD","LU0689472784.USD","LU1551013342.USD","BK4139","LU0640476718.USD"],"gpt_icon":0},{"id":"2489605467","title":"CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2489605467","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489605467?lang=en_us&edition=fundamental","pubTime":"2024-12-06 00:35","pubTimestamp":1733416538,"startTime":"0","endTime":"0","summary":"On Thursday, CG Oncology, Inc.  revealed topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer  unresponsive to Bacillus Calmette Guerin .The trial demonstrated that 74.5% of patients  achieved a complete response  at any time after receiving treatment with cretostimogene as a single agent.The median duration of response  has not been reached but exceeds 27 months as of the data cutoff of September 30.Gary Steinberg, Professor, Department of Urology at Rush University Medical Center, said, “I am very encouraged by the latest data from the BOND-003 study, which demonstrates cretostimogene’s compelling efficacy as well as its potential to induce a best-in-class durable response in NMIBC patients, with 63.5% of patients remaining in response at 12 months or greater and 56.6% of patients remaining in response at 24 months or greater, by K-M estimate. Additionally, 97.3% of patients were free from progression to Muscle Invasive Bladder Ca","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HEWmOk2Oa.dWxKly0Ikk.w--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a919db55789307d3b71f71634a9d2cbd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HEWmOk2Oa.dWxKly0Ikk.w--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a919db55789307d3b71f71634a9d2cbd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-touts-encouraging-data-163538076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","CG","BK4139","BCG","CGON","IE00BGHQF748.EUR","SSI","IE00B64PRP62.GBP","BK4135","IE00B3QW5Z07.USD","BK4161"],"gpt_icon":0},{"id":"2489598674","title":"CG Oncology Reports Promising Phase 3 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2489598674","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489598674?lang=en_us&edition=fundamental","pubTime":"2024-12-05 21:17","pubTimestamp":1733404675,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc. ( ($CGON) ) has provided an announcement. CG Oncology, Inc. announced promising results from their Phase 3 BOND-003 trial, showin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cg-oncology-reports-promising-phase-3-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cg-oncology-reports-promising-phase-3-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGON","US7Y.BOND","US10Y.BOND","US12M.BOND","CG","IE00B3QW5Z07.USD","US5Y.BOND","US6M.BOND","IE00BGHQF748.EUR","US2Y.BOND","BK4139","US3Y.BOND","US30Y.BOND","BK4135","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2489573458","title":"CG Oncology announces data from Phase 3 BOND-003 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2489573458","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489573458?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:10","pubTimestamp":1733400641,"startTime":"0","endTime":"0","summary":"CG Oncology (CGON) announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer, NMBIC, unr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cg-oncology-announces-data-from-phase-3-bond-003-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cg-oncology-announces-data-from-phase-3-bond-003-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BGHQF748.EUR","US30Y.BOND","BOND","BK4139","BK4135","US3Y.BOND","US6M.BOND","IE00B64PRP62.GBP","US12M.BOND","BK4585","US2Y.BOND","US5Y.BOND","US10Y.BOND","BK4588","IE00B3QW5Z07.USD","CG","US7Y.BOND","CGON"],"gpt_icon":0},{"id":"2489440430","title":"BRIEF-CG Oncology Announces 74.5% Complete Response In Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2489440430","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489440430?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:06","pubTimestamp":1733400374,"startTime":"0","endTime":"0","summary":"Dec 5  - CG Oncology Inc   :   * GROUNDBREAKING CRETOSTIMOGENE GRENADENOREPVEC MONOTHERAPY DATA DEMONSTRATES SUSTAINED, DURABLE COMPLETE RESPONSES IN HIGH-RISK BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER   * CG ONCOLOGY INC - ANNOUNCES 74.5% COMPLETE RESPONSE IN PHASE 3 TRIAL   * CG ONCOLOGY INC - NO GRADE 3 OR GREATER TREATMENT-RELATED ADVERSE EVENTS REPORTEDSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","CG","CGON","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4135","BK4139"],"gpt_icon":0},{"id":"2489643034","title":"CG Oncology Inc - Announces 74.5% Complete Response in Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2489643034","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489643034?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:00","pubTimestamp":1733400002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nTUA8P5VFF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2489430338","title":"Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2489430338","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489430338?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:00","pubTimestamp":1733400002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nTUA8P5VFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2489430328","title":"CG Oncology Inc - No Grade 3 or Greater Treatment-Related Adverse Events Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2489430328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489430328?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:00","pubTimestamp":1733400002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nTUA8P5VFF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2489430673","title":"Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2489430673","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489430673?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:00","pubTimestamp":1733400000,"startTime":"0","endTime":"0","summary":"– 74.5% of patients achieved a complete response at any time –。– Median duration of response is greater than 27 months and not reached –。– Latest data update continued to show favorable safety and tolerability results –。– Company hosting virtual investor event with lead investigator at 8 am EST today –。There were no Grade 3 or greater treatment-related adverse events  or deaths reported. No treatment-related discontinuation of cretostimogene was observed. 97.3% of patients completed all expected treatments, demonstrating favorable patient adherence and compliance. The most common TRAEs  were bladder spasm, pollakiuria, micturition urgency, dysuria, and hematuria.“The BOND-003 monotherapy data underscores our novel investigational oncolytic immunotherapy’s unique product profile, including its dual mechanism of action, which we believe differentiates it from current and investigational NMIBC treatments,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “Based upon t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PGAn7Ub.kbtQmM44hCDcNw--~B/aD0xOTE7dz0xMTI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/15e379d5feda7db9477b0d6dfc1496ab","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PGAn7Ub.kbtQmM44hCDcNw--~B/aD0xOTE7dz0xMTI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/15e379d5feda7db9477b0d6dfc1496ab"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/groundbreaking-cretostimogene-grenadenorepvec-monotherapy-data-120000639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","BCG","BK4139","BK4135","CGON","CR"],"gpt_icon":0},{"id":"2488769416","title":"CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2488769416","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488769416?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:00","pubTimestamp":1733144400,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., Dec.  02, 2024  (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bla","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/02/2989764/0/en/CG-Oncology-to-Host-Conference-Call-and-Webcast-on-BOND-003-Data-on-Thursday-December-5-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","CG","CGON","BK4181","HST","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4218","BOND","IE00B3QW5Z07.USD","BK4135"],"gpt_icon":0},{"id":"2484115884","title":"CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2484115884","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484115884?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:00","pubTimestamp":1732107600,"startTime":"0","endTime":"0","summary":"Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials in Progress PostersIRVINE, Calif., Nov.  20, 2024","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/20/2984393/0/en/CG-Oncology-to-Present-Results-on-Cretostimogene-Grenadenorepvec-at-the-Society-of-Urologic-Oncology-SUO-25th-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4139","CG","CGON","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BCG","IE00B64PRP62.GBP"],"gpt_icon":1}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":119,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CGON\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"CGON","fiscalQuarterEnding":"2025/03","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2025-03-28","symbol":"CGON","fiscalQuarterEnding":"2024/12","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.48},{"market":"US","date":"2024-11-12","symbol":"CGON","fiscalQuarterEnding":"2024/09","expectedEps":-0.42,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CGON\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CGON\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1,"buy":0.8,"hold":0.1,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":10,"updateTime":1746244800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CGON\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CGON","date":"2025-05-13","current":-21.782868,"percent":0.924837,"low":-77.942097,"twenty":-49.980959,"median":-38.949194,"eighty":-27.956186,"high":-13.496527,"avg":-39.817545,"sd":14.152919,"marketCap":1917741922},"quantilePoints":[{"date":"2024-01-26","current":-62.124194,"twenty":-62.124194,"median":-62.124194,"eighty":-62.124194,"marketCap":2539823423},{"date":"2024-02-02","current":-61.712969,"twenty":-61.712969,"median":-60.379514,"eighty":-59.355029,"marketCap":2523011292},{"date":"2024-02-09","current":-63.452965,"twenty":-62.124194,"median":-60.590915,"eighty":-59.355029,"marketCap":2594147579},{"date":"2024-02-16","current":-77.177799,"twenty":-70.608092,"median":-61.918582,"eighty":-60.168112,"marketCap":3155259972},{"date":"2024-02-23","current":-75.080046,"twenty":-72.448911,"median":-64.672589,"eighty":-60.20714,"marketCap":3069497532},{"date":"2024-03-01","current":-72.705845,"twenty":-73.870179,"median":-70.608092,"eighty":-60.516111,"marketCap":2972433066},{"date":"2024-03-08","current":-64.818944,"twenty":-72.891228,"median":-69.827533,"eighty":-60.799064,"marketCap":2649992888},{"date":"2024-03-15","current":-60.493345,"twenty":-72.302556,"median":-67.469593,"eighty":-60.20714,"marketCap":2473149409},{"date":"2024-03-22","current":-66.867912,"twenty":-72.162706,"median":-65.355579,"eighty":-60.438055,"marketCap":2733760852},{"date":"2024-03-28","current":-56.207672,"twenty":-71.967566,"median":-64.762028,"eighty":-59.842879,"marketCap":2732086332},{"date":"2024-04-05","current":-51.752186,"twenty":-71.648838,"median":-63.50175,"eighty":-58.14191,"marketCap":2515518513},{"date":"2024-04-12","current":-54.631116,"twenty":-71.284577,"median":-62.382039,"eighty":-56.136384,"marketCap":2655454642},{"date":"2024-04-19","current":-48.420853,"twenty":-71.001624,"median":-61.712969,"eighty":-54.576279,"marketCap":2353592420},{"date":"2024-04-26","current":-49.627262,"twenty":-70.73168,"median":-60.54213,"eighty":-53.208102,"marketCap":2412232322},{"date":"2024-05-03","current":-54.151294,"twenty":-70.286112,"median":-60.183337,"eighty":-53.600185,"marketCap":2632131954},{"date":"2024-05-10","current":-35.176138,"twenty":-69.778748,"median":-59.371617,"eighty":-52.278619,"marketCap":2000537303},{"date":"2024-05-17","current":-36.289307,"twenty":-68.393255,"median":-58.232975,"eighty":-49.860318,"marketCap":2063845445},{"date":"2024-05-24","current":-35.140985,"twenty":-67.52163,"median":-57.330453,"eighty":-49.032283,"marketCap":1998538098},{"date":"2024-05-31","current":-40.179539,"twenty":-67.228921,"median":-56.207672,"eighty":-47.173317,"marketCap":2285090743},{"date":"2024-06-07","current":-40.894311,"twenty":-66.477632,"median":-55.878652,"eighty":-42.192617,"marketCap":2325741235},{"date":"2024-06-14","current":-40.788853,"twenty":-65.885708,"median":-55.522213,"eighty":-41.278647,"marketCap":2319743621},{"date":"2024-06-21","current":-37.625109,"twenty":-65.85969,"median":-54.631116,"eighty":-40.788853,"marketCap":2139815216},{"date":"2024-06-28","current":-35.445642,"twenty":-65.443392,"median":-54.494024,"eighty":-40.683395,"marketCap":2015864537},{"date":"2024-07-05","current":-36.125261,"twenty":-64.796178,"median":-54.151294,"eighty":-39.560851,"marketCap":2054515824},{"date":"2024-07-12","current":-40.378738,"twenty":-64.675841,"median":-53.136814,"eighty":-38.206301,"marketCap":2296419569},{"date":"2024-07-15","current":-41.491907,"twenty":-64.64657,"median":-52.780375,"eighty":-38.236766,"marketCap":2359727711},{"date":"2024-08-02","current":-39.652248,"twenty":-64.6173,"median":-52.752957,"eighty":-38.267232,"marketCap":2255102676},{"date":"2024-08-09","current":-38.949194,"twenty":-63.924553,"median":-51.752186,"eighty":-38.000071,"marketCap":2215118586},{"date":"2024-08-16","current":-40.572681,"twenty":-63.472479,"median":-49.956283,"eighty":-38.105529,"marketCap":2307449488},{"date":"2024-08-23","current":-42.377221,"twenty":-62.965116,"median":-49.723226,"eighty":-38.189896,"marketCap":2410077328},{"date":"2024-08-30","current":-43.2618,"twenty":-62.33047,"median":-48.934948,"eighty":-38.276606,"marketCap":2460385093},{"date":"2024-09-06","current":-44.299706,"twenty":-62.063778,"median":-48.270052,"eighty":-38.375033,"marketCap":2519412871},{"date":"2024-09-13","current":-41.079839,"twenty":-61.869081,"median":-45.980618,"eighty":-38.588613,"marketCap":2336292606},{"date":"2024-09-20","current":-46.127835,"twenty":-61.368222,"median":-44.806865,"eighty":-38.861791,"marketCap":2623382252},{"date":"2024-09-27","current":-43.379744,"twenty":-60.747027,"median":-44.736098,"eighty":-39.046612,"marketCap":2467092795},{"date":"2024-10-04","current":-42.412604,"twenty":-60.551887,"median":-44.517902,"eighty":-39.324835,"marketCap":2412089639},{"date":"2024-10-11","current":-40.667036,"twenty":-60.382766,"median":-44.458898,"eighty":-39.52313,"marketCap":2312815649},{"date":"2024-10-18","current":-43.356155,"twenty":-60.203473,"median":-44.063818,"eighty":-39.574912,"marketCap":2465751255},{"date":"2024-10-25","current":-42.990529,"twenty":-60.177247,"median":-43.698192,"eighty":-39.657154,"marketCap":2444957379},{"date":"2024-10-31","current":-42.837202,"twenty":-60.01213,"median":-43.662809,"eighty":-39.673778,"marketCap":2436237366},{"date":"2024-11-08","current":-46.068863,"twenty":-59.381569,"median":-43.651015,"eighty":-39.804577,"marketCap":2620028401},{"date":"2024-11-15","current":-32.980568,"twenty":-59.208121,"median":-43.63922,"eighty":-39.654701,"marketCap":2400853462},{"date":"2024-11-22","current":-30.044833,"twenty":-58.542987,"median":-43.538968,"eighty":-38.997903,"marketCap":2187143689},{"date":"2024-11-29","current":-32.283796,"twenty":-58.232975,"median":-43.444613,"eighty":-38.328163,"marketCap":2350131206},{"date":"2024-12-06","current":-31.17825,"twenty":-58.005312,"median":-43.379744,"eighty":-38.000071,"marketCap":2269651893},{"date":"2024-12-13","current":-26.821099,"twenty":-57.745125,"median":-43.279491,"eighty":-37.543086,"marketCap":1952468717},{"date":"2024-12-20","current":-26.031423,"twenty":-56.915781,"median":-43.120267,"eighty":-36.394765,"marketCap":1894983493},{"date":"2024-12-27","current":-27.044066,"twenty":-56.349294,"median":-43.061296,"eighty":-36.125261,"marketCap":1968699839},{"date":"2025-01-03","current":-26.914002,"twenty":-56.207672,"median":-43.037707,"eighty":-35.33784,"marketCap":1959231684},{"date":"2025-01-10","current":-28.298257,"twenty":-56.136384,"median":-42.978735,"eighty":-34.953504,"marketCap":2059999900},{"date":"2025-01-17","current":-27.034776,"twenty":-55.969133,"median":-42.872585,"eighty":-33.374909,"marketCap":1968023542},{"date":"2025-01-24","current":-32.158189,"twenty":-55.840266,"median":-42.689773,"eighty":-32.852839,"marketCap":2340987506},{"date":"2025-01-31","current":-31.530712,"twenty":-55.653821,"median":-42.565931,"eighty":-32.283796,"marketCap":2295309701},{"date":"2025-02-07","current":-31.405216,"twenty":-55.437216,"median":-42.394913,"eighty":-32.036945,"marketCap":2286174140},{"date":"2025-02-14","current":-29.805151,"twenty":-55.004006,"median":-42.206678,"eighty":-31.677123,"marketCap":2169695737},{"date":"2025-02-21","current":-29.512328,"twenty":-54.631116,"median":-41.999801,"eighty":-31.530712,"marketCap":2148379428},{"date":"2025-02-28","current":-25.768383,"twenty":-54.494024,"median":-41.775708,"eighty":-31.373843,"marketCap":1875835192},{"date":"2025-03-07","current":-28.226,"twenty":-54.39406,"median":-41.609082,"eighty":-31.094637,"marketCap":2054739928},{"date":"2025-03-14","current":-27.138374,"twenty":-54.151294,"median":-41.292708,"eighty":-30.560445,"marketCap":1975565066},{"date":"2025-03-21","current":-29.020804,"twenty":-53.671473,"median":-41.068045,"eighty":-30.21301,"marketCap":2112598481},{"date":"2025-03-28","current":-28.173711,"twenty":-53.493253,"median":-40.922206,"eighty":-29.826066,"marketCap":2050933444},{"date":"2025-04-04","current":-16.223536,"twenty":-52.780375,"median":-40.788853,"eighty":-29.478125,"marketCap":1428303862},{"date":"2025-04-11","current":-15.26259,"twenty":-52.725539,"median":-40.592885,"eighty":-29.073094,"marketCap":1343703153},{"date":"2025-04-17","current":-17.504797,"twenty":-52.648767,"median":-40.36956,"eighty":-28.807616,"marketCap":1541104808},{"date":"2025-04-25","current":-18.630229,"twenty":-51.927664,"median":-39.710836,"eighty":-28.715432,"marketCap":1640186719},{"date":"2025-05-02","current":-24.014988,"twenty":-51.631545,"median":-39.587801,"eighty":-28.276198,"marketCap":2114255557},{"date":"2025-05-09","current":-20.891121,"twenty":-50.318205,"median":-39.192738,"eighty":-28.046644,"marketCap":1839233409},{"date":"2025-05-13","current":-21.782868,"twenty":-49.980959,"median":-38.949194,"eighty":-27.956186,"marketCap":1917741922}],"updateTime":1747258654021}}}